---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011071"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:18:39.293233+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025

## Summary
- Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.
- Cash, equivalents and marketable securities at $371M as of June 30; runway into 2027.
- First participants dosed in Phase 1a SAD of anti-tau antibody VY7523; top-line safety/PK data expected H1 2025.
- Three gene therapy INDs on track for 2025: SOD1 ALS (VY9323), GBA1, and Friedreich's ataxia.
- Appointed Nathan Jorgensen as CFO; received $3M milestone from Neurocrine for GBA1 candidate selection.

## SEC filing metadata
- accession: 0001558370-24-011071
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000155837024011071/0001558370-24-011071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000155837024011071/vygr-20240806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011071
- JSON: https://secwatch.observer/filing/0001558370-24-011071.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.